Loading...
Antiplatelet therapy is one of the most commonly used therapies for prevention of recurrent events in patients with ischemic stroke or transient ischemic attack (TIA). Prevention of recurrent ischemic events is intended to offset a potential increase in bleeding. To examine how this bleeding risk changes over time, researchers combined data from six large secondary prevention trials that evaluated either single or dual antiplatelet therapy. The authors evaluated major bleeds, gastrointestinal bleeding events, and intracranial hemorrhage during several time periods after study enrollment: ≤30 days, 31 to 90 days (reference period), 91 to 180 days, 181 to 365 days, and >365 days. Major bleeds were defined as events that were fatal, intracrani…